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The many faces of C3
glomerulopathy
To the Editor: The recent article by Sethi et al.,1
‘Membranoproliferative glomerulonephritis and C3 glomer-
ulopathy: resolving the confusion’, made me revisit a
12-year-old publication.
In ‘Apparent progression of acute glomerulonephritis to
dense deposit disease’2 we described an 8-year-old boy with
hypocomplementemia and meningococcemia. The ﬁrst
kidney biopsy showed glomeruli with abundant deposits of
C3 and scarce deposits of IgG. Typical subepithelial humps
were observed ultrastucturally, with only occasional sub-
endothelial and intramembranous deposits. Two years later, a
new biopsy was again positive for C3, and intramembranous,
electron dense ribbon-like change, typical of dense-deposit
disease (DDD), was present along the capillary loops, with
only occasional subepithelial humps.
In view of the clinical history of our patient, and the typical
ﬁndings of DDD in the second biopsy, I suggest that the
ﬁrst biopsy, with its scarce subendothelial deposits and
no membranoproliferative pattern, might also represent C3
glomerulopathy, similar to cases described by Fakhouri et al.3
and Servais et al.4 One might propose that our case illustrates
that C3 glomerulopathy can present with variable faces in the
same patient.
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The Authors Reply: We thank Dr Meleg-Smith for her
letter1 in response to our article.2 The case you describe of
postinfectious glomerulonephritis following meningococcemia
progressing to dense-deposit disease (DDD) is very interest-
ing. We have seen similar cases of postinfectious glomer-
ulonephritis progressing to either C3 glomerulonephritis
(C3GN) or DDD.
We believe that such cases truly start off as postinfectious
glomerulonephritis, and the infection triggers activation of
the alternative pathway of complement. However, due to an
underlying defect in the regulating mechanisms of the alter-
native pathway of complement, such as mutations in or antibodies
to the complement regulating proteins, the alternative pathway
does not revert back to baseline even after the infection is
controlled. The consequence is glomerular deposition of com-
plement factors with development of a proliferative glomeru-
lonephritis. If the alternative pathway is slowly brought under
control, one is likely to see a mesangial proliferative glomeru-
lonephritis in a subsequent biopsy; if the alternative pathway
is chronically activated, a membranoproliferative glomerulo-
nephritis can result.
Whether the activation of alternative pathway leads to a
C3GN or DDD may depend on factors such as the site and
severity of dysregulation of the alternative pathway. We have
also seen cases of transition from a C3GN to DDD phenotype
with some loops showing capillary wall deposits typical of
C3GN and other loops showing intramembranous deposits of
DDD. Thus, as you rightly point out, there are many faces of
dysregulation of the alternative pathway of complement. We
need to be aware of the heterogeneity in renal biopsy ﬁndings
to correctly diagnose and manage patients with alternative
pathway abnormalities.
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